La trayectoria de la Dra. Daphne Nunille González Muñoz es una historia de perseverancia, pasión y determinación, un ejemplo de cómo la dedicación de una persona puede traspasar fronteras y generaciones.
We’re excited to announce Industry-led webinars, hosted by the SVS Foundation, that will convene leading experts to present the latest evidence, case-based discussions and real-world insights shaping vascular access and endovascular care.
Disclaimer: These webinars are the sole content of the Industry Sponsors and do NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies, or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.
Wednesday, December 9 | 6:00 p.m. CT
Joseph Liechty, MD, Texas Vascular Associates / Baylor Scott & White Health
Sara Rose-Sauld, DPM, Mass General Brigham
Join Stryker for an overview of the LimFlow patient journey, from identifying appropriate candidates to achieving wound healing. This webinar will explore key patient selection considerations, provide a high-level overview of the Transcatheter Arterialization of the Deep Veins (TADV) procedure, and highlight post-TADV wound care and management. Real-world clinical cases will illustrate each stage of the patient journey, offering practical insights into patient care and the path to wound healing.
Missed the webinars or want a replay? The full recordings are now available to watch on demand on SVS VascuLEARN.
As DVT intervention continues to evolve, treatment success should be defined by patient outcomes — not procedural efficiency alone. This webinar will explore the importance of complete thrombus removal, identifying acute thrombus, and the impact on outcomes such as re-thrombosis and patient recovery. Speakers will also review key insights from the CLOUT study and discuss how this data supports a comprehensive mechanical thrombectomy approach with ClotTriever.
This webinar will provide an overview of the current treatment landscape for arterial thromboembolism, highlighting unmet clinical needs addressed by the Artix thrombectomy system. Attendees will also gain insights into the latest clinical data supporting Artix, along with real-world case examples demonstrating its practical application.
Adam Gwozdz, Stryker
Anahita Dua, MD
Khanjan 'KJ' Nagarsheth, MD
Disclaimer: These webinars are the sole content of the Industry Sponsors and do NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.
Join leading experts for an in-depth discussion on the science, clinical outcomes and real-world application of Symvess® Acellular Tissue Engineered Vessel (ATEV), a conduit innovation in vascular surgery in the last four decades specifically for the vascular trauma indication.
Laura Niklason, MD, PhD, Founder, President, and CEO, Humacyte
Dr. Niklason will provide an overview of Humacyte and a scientific analysis of the Symvess® Acellular Tissue Engineered Vessel (ATEV™) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.1
Todd Rasmussen, MD, Vascular Surgeon
Dr. Rasmussen will review ATEV clinical evidence from completed studies and patient cases, and provide insights into intraoperative ATEV handling techniques.
Interactive Discussion
The program will conclude with a live discussion session to address audience questions hosted by Dr. Niklason and Dr. Rasmussen, giving attendees the opportunity to engage directly with the faculty and explore this innovation in greater depth.
The United States FDA approval of the Symvess® Acellular Tissue Engineered Vessel (ATEV) for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible represents one of the only conduit innovations in vascular surgery in the last four decades specifically for the vascular trauma indication.1 Symvess is a bioengineered human vessel that is readily available off-the-shelf and is designed to repopulate with the patient’s own cells over time.1
Reference
INDICATION: SYMVESS is an acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity arterial injury when urgent revascularization is needed to avoid imminent limb loss, and autologous vein graft is not feasible.
BOXED WARNING: GRAFT FAILURE: loss of SYMVESS integrity due to mid-graft rupture or anastomotic failure can result in life threatening hemorrhage.
DO NOT use SYMVESS in patients who have a medical condition that would preclude long-term antiplatelet therapy after acute injury resolution.
Warnings and Precautions: Vascular Graft Rupture, Anastomotic Failure, and Thrombosis have occurred in patients treated with SYMVESS. SYMVESS is manufactured using cells and reagents that may transmit infectious diseases or agents; none have been reported during clinical testing.
Adverse Reactions: The most common (≥3%): thrombosis, fever, pain, anastomotic stenosis, rupture or anastomotic failure, and infection.
Click here to obtain a copy of the Symvess
U.S. Prescribing Information and Boxed Warning
and see above for Important Safety Information
Trademarks are owned by Humacyte Global Inc.
© 2026 Humacyte Global, Inc. All Rights Reserved. US-SYM-000321 3/26
Disclaimer: These webinars are the sole content of the Industry Sponsors and do NOT constitute an endorsement by the SVS or the SVS Foundation for any products, therapies or speaker remarks. The speakers are selected by the Industry Sponsors, and their remarks are their own.
Challenges in AV fistula creation and durability persist despite adherence to traditional creation strategies. This webinar explores how hemodynamic insights and extravascular support are informing a more refined, data-driven algorithm of care.
This webinar will examine how:
Learn how extravascular support can lead to improvements in:
Designed for vascular surgeons and professionals across the dialysis care continuum, the discussion will bridge research foundations with practical decision-making to support improved outcomes in access creation and long-term maintenance.
Up to 10% of patients with chronic limb-threatening ischemia (CLTI) have exhausted all conventional revascularization options and face a devastating risk of major amputation. Transcatheter arterialization of the deep veins (TADV) with the purpose-built LimFlow System is redefining what’s possible for these no-option patients by restoring blood flow to the foot through the venous system.
Following the encouraging limb-salvage and functional outcomes demonstrated in PROMISE I and the pivotal PROMISE II trial, the PROMISE III study takes the next step—prospectively examining both clinical outcomes and the physiologic maturation of the TADV circuit. In this exclusive webinar, investigators unveil the 6-month primary endpoint results from PROMISE III, showcasing real-world hemodynamic evolution, circuit maturation, and wound-healing patterns that deepen our understanding of how LimFlow works and who benefits most.
Join us for an in-depth discussion on how this innovative therapy is expanding treatment possibilities and reshaping the care paradigm for patients with no-option CLTI.
Learning Objectives:
Speakers:
Dr. Jocelyn Beach | Dartmouth Health
Dr. Daniel Clair | Vanderbilt University Medical Center
Dr. Adam Gwozdz | Inari/Stryker
Discover how VasQ is reshaping fistula care and delivering meaningful results for patients with ESKD.
This session will highlight the latest clinical evidence on the Eluvia Drug-Eluting Stent (DES), including insights from the SPORTS RCT, Eluvia Pooled Meta-Analysis, and Eluvia TRUE-PTX data. Faculty experts will discuss how these findings reinforce Eluvia’s advantages over alternative modalities—particularly in treating long, challenging lesions.
Through case-based discussions and interactive dialogue, participants will gain practical strategies for integrating DES therapy into real-world practice and comparing its role to DCB and BMS approaches.
Key topics include:
Don’t miss this opportunity to deepen your knowledge and explore how DES therapy can improve outcomes for patients with PAD and CLI.
Nacido en 1983 en el seno de una familia de trabajadores agrícolas migrantes en la cuidad de Yuba, California, el Dr. Jesús G. Ulloa tiene sus raíces firmemente arraigadas en los valores del trabajo duro y la familia.
Born in 1983 to migrant farm workers in Yuba City, California, Dr. Jesús G. Ulloa’s roots are firmly planted in the values of hard work and family.
Concepción Montaño Ramírez, RN, a familiar name to many who participate in the SVS Foundation September Vascular Health Step Challenge, has been the challenge’s Top Walker for the past three years. Within that time, she has walked over 329 miles and was honored by the Foundation as a legacy walker in this year’s Step Challenge. Beyond the leaderboard, the people around her regard her as a symbol of resilience, inspiration and a legacy in action with how her family history is deeply intertwined with vascular health.
This article was sponsored by the SVS Foundation.
Dr. Enrico Ascher’s journey in vascular surgery began in Rio de Janeiro, where his fascination with human anatomy led him to pursue a career in medicine at the Federal University of Rio de Janeiro.
Dr. Caron B. Rockman’s legacy is one of leadership, compassion and relentless pursuit of better outcomes for her patients. Her voice in vascular surgery resonates in her research and leadership, as well as in every patient she treats.